Published in Prog Neurobiol on January 09, 2007
Adenosine receptors as drug targets--what are the challenges? Nat Rev Drug Discov (2013) 1.74
The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol (2007) 1.72
Adenosine as a neuromodulator in neurological diseases. Curr Opin Pharmacol (2007) 1.61
Adenosine A(2A) receptor mediates microglial process retraction. Nat Neurosci (2009) 1.56
Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics (2012) 0.98
Static magnetic field exposure reproduces cellular effects of the Parkinson's disease drug candidate ZM241385. PLoS One (2010) 0.90
GDNF control of the glutamatergic cortico-striatal pathway requires tonic activation of adenosine A receptors. J Neurochem (2009) 0.90
Functional changes in postsynaptic adenosine A(2A) receptors during early stages of a rat model of Huntington disease. Exp Neurol (2011) 0.86
Modulators of nucleoside metabolism in the therapy of brain diseases. Curr Top Med Chem (2011) 0.83
Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay. Neurobiol Dis (2011) 0.82
When cytokinin, a plant hormone, meets the adenosine A2A receptor: a novel neuroprotectant and lead for treating neurodegenerative disorders? PLoS One (2012) 0.82
A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Mol Psychiatry (2014) 0.81
Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's disease. Front Cell Neurosci (2014) 0.81
Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies. Mol Neurobiol (2013) 0.81
Modulation of excitatory neurotransmission by neuronal/glial signalling molecules: interplay between purinergic and glutamatergic systems. Purinergic Signal (2015) 0.78
Adenosine A(2A) receptors modulate BDNF both in normal conditions and in experimental models of Huntington's disease. Purinergic Signal (2007) 0.78
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med (2006) 4.36
Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation (2007) 3.65
Tau phosphorylation and sevoflurane anesthesia: an association to postoperative cognitive impairment. Anesthesiology (2012) 2.87
Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci (2006) 2.81
Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain (2006) 2.71
Ephrin signalling controls brain size by regulating apoptosis of neural progenitors. Nature (2005) 2.33
Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci (2005) 2.32
The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J (2006) 2.17
Electrosurgery and implantable electronic devices: review and implications for office-based procedures. Dermatol Surg (2011) 2.07
Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J Neurosci (2002) 2.02
Purinergic signalling: from normal behaviour to pathological brain function. Prog Neurobiol (2011) 1.76
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med (2007) 1.69
3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem (2005) 1.68
Symptoms of B12 deficiency can occur in women of child bearing age supplemented with folate. Neurology (2002) 1.63
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 1.62
Astrocytes in the damaged brain: molecular and cellular insights into their reactive response and healing potential. Biochem Pharmacol (2009) 1.61
Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) (2001) 1.57
Nucleotide-mediated calcium signaling in rat cortical astrocytes: Role of P2X and P2Y receptors. Glia (2003) 1.54
Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci (2003) 1.53
Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol (2012) 1.49
Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology (2008) 1.45
Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J (2009) 1.44
The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS One (2008) 1.44
Cardiac effects of adenosine in A(2A) receptor knockout hearts: uncovering A(2B) receptors. Am J Physiol Heart Circ Physiol (2002) 1.43
Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis. J Immunol (2006) 1.43
Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology (2005) 1.41
Premature ovarian aging in mice deficient for Gpr3. Proc Natl Acad Sci U S A (2005) 1.41
Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res (2012) 1.41
To be or not to be (inflamed)--is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends Pharmacol Sci (2005) 1.39
Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol (2009) 1.36
CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology (2005) 1.33
Purinergic signalling in inflammation of the central nervous system. Trends Neurosci (2009) 1.32
Targeted deletion of adenosine A(3) receptors augments adenosine-induced coronary flow in isolated mouse heart. Am J Physiol Heart Circ Physiol (2002) 1.27
Cloning, pharmacological characterisation and distribution of the rat G-protein-coupled P2Y(13) receptor. Biochem Pharmacol (2004) 1.26
Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci (2005) 1.26
Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica (2011) 1.25
Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol (2008) 1.25
Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology (2004) 1.25
Pathophysiological roles of extracellular nucleotides in glial cells: differential expression of purinergic receptors in resting and activated microglia. Brain Res Brain Res Rev (2005) 1.24
Low ethanol sensitivity and increased ethanol consumption in mice lacking adenosine A2A receptors. J Neurosci (2002) 1.22
Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics (2008) 1.21
Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postconditioning. Am J Physiol Heart Circ Physiol (2007) 1.17
CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. Biochem Pharmacol (2005) 1.17
Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J Neurosci (2007) 1.16
Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J (2008) 1.16
Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal. J Cell Sci (2005) 1.13
CysLT1 receptor is a target for extracellular nucleotide-induced heterologous desensitization: a possible feedback mechanism in inflammation. J Cell Sci (2005) 1.13
Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer. Cancer Res (2010) 1.13
Aggravated brain damage after hypoxic ischemia in immature adenosine A2A knockout mice. Stroke (2003) 1.12
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther (2003) 1.12
Decreased alcohol self-administration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice. Neuropharmacology (2004) 1.12
Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain (2008) 1.11
A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur J Pharmacol (2002) 1.10
A role for P2X7 in microglial proliferation. J Neurochem (2006) 1.10
Up-regulation of A 2B adenosine receptor in A 2A adenosine receptor knockout mouse coronary artery. J Mol Cell Cardiol (2008) 1.10
Endogenous adenosine increases coronary flow by activation of both A2A and A2B receptors in mice. J Cardiovasc Pharmacol (2003) 1.09
Effects of remifentanil on N-methyl-D-aspartate receptor: an electrophysiologic study in rat spinal cord. Anesthesiology (2005) 1.08
From tau phosphorylation to tau aggregation: what about neuronal death? Biochem Soc Trans (2010) 1.08
Enhanced airway reactivity and inflammation in A2A adenosine receptor-deficient allergic mice. Am J Physiol Lung Cell Mol Physiol (2007) 1.07
Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A(2B) receptor. Eur J Immunol (2008) 1.07
The P2Y-like receptor GPR17 as a sensor of damage and a new potential target in spinal cord injury. Brain (2009) 1.07
The influence of comorbid depression on quality of life for people with epilepsy. Epilepsy Behav (2003) 1.07
BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem (2007) 1.07
Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-β1-42 oligomers are revealed in vivo by using a novel animal model. J Neurosci (2012) 1.06
Involvement of nitric oxide in depolarization-induced suppression of inhibition in hippocampal pyramidal cells during activation of cholinergic receptors. J Neurosci (2007) 1.06
Purinoceptor-mediated calcium signaling in primary neuron-glia trigeminal cultures. Cell Calcium (2007) 1.05
Phenotypic changes, signaling pathway, and functional correlates of GPR17-expressing neural precursor cells during oligodendrocyte differentiation. J Biol Chem (2011) 1.05
Invasive palliative interventions: when are they worth it and when are they not? Cancer J (2010) 1.04
Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur J Neurosci (2002) 1.04
A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease. Neurobiol Dis (2009) 1.04
Altered neuronal excitability in cerebellar granule cells of mice lacking calretinin. J Neurosci (2003) 1.04
The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J (2007) 1.04
Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia (2003) 1.03
Role of CYP epoxygenases in A2A AR-mediated relaxation using A2A AR-null and wild-type mice. Am J Physiol Heart Circ Physiol (2008) 1.03
The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons. Implication in a pathological mechanism related to Alzheimer disease. J Biol Chem (2006) 1.03
Development of an immobilized GPR17 receptor stationary phase for binding determination using frontal affinity chromatography coupled to mass spectrometry. Anal Biochem (2008) 1.02
Temporomandibular joint inflammation activates glial and immune cells in both the trigeminal ganglia and in the spinal trigeminal nucleus. Mol Pain (2010) 1.01
Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol (2006) 1.01
Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem Biophys Res Commun (2002) 1.01
Interactions between A(2A) adenosine receptors, hydrogen peroxide, and KATP channels in coronary reactive hyperemia. Am J Physiol Heart Circ Physiol (2013) 1.00
The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy. Epilepsy Behav (2004) 1.00
Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology. Neurobiol Dis (2011) 1.00
The influence of comorbid depression on seizure severity. Epilepsia (2003) 0.99
A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J Neurosci (2003) 0.98
Contributions of A2A and A2B adenosine receptors in coronary flow responses in relation to the KATP channel using A2B and A2A/2B double-knockout mice. Am J Physiol Heart Circ Physiol (2011) 0.98
Minocycline in phenotypic models of Huntington's disease. Neurobiol Dis (2005) 0.98
Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC. Eur J Neurosci (2004) 0.98
Functional characterization of two isoforms of the P2Y-like receptor GPR17: [35S]GTPgammaS binding and electrophysiological studies in 1321N1 cells. Am J Physiol Cell Physiol (2009) 0.97
The regulated expression, intracellular trafficking, and membrane recycling of the P2Y-like receptor GPR17 in Oli-neu oligodendroglial cells. J Biol Chem (2013) 0.97
Absence of adenosine-mediated aortic relaxation in A(2A) adenosine receptor knockout mice. Am J Physiol Heart Circ Physiol (2009) 0.97
The lack of A2A adenosine receptors diminishes the reinforcing efficacy of cocaine. Neuropsychopharmacology (2006) 0.96
The GPR17 receptor in NG2 expressing cells: focus on in vivo cell maturation and participation in acute trauma and chronic damage. Glia (2011) 0.96
Extrinsic purinergic regulation of neural stem/progenitor cells: implications for CNS development and repair. Stem Cell Rev (2012) 0.96